CA2281420C - Preparation of pharmaceutically-active granules - Google Patents
Preparation of pharmaceutically-active granules Download PDFInfo
- Publication number
- CA2281420C CA2281420C CA002281420A CA2281420A CA2281420C CA 2281420 C CA2281420 C CA 2281420C CA 002281420 A CA002281420 A CA 002281420A CA 2281420 A CA2281420 A CA 2281420A CA 2281420 C CA2281420 C CA 2281420C
- Authority
- CA
- Canada
- Prior art keywords
- particles
- coating
- pharmaceutically active
- microcrystalline cellulose
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Abstract
The present invention provides a core of predominately microcrystalline cellulose, on which an active drug is layered onto the core via solution coating. The coated particles have a narrower particle size distribution than coated granules provided by other processes. An optional final coating of a pharmaceutically acceptable polymeric coating is provided to provide tastemaking or controlled release, and protection of the drug-layered particles.
Description
PREPARATION OF PHARMACEUTICALLY ACTIVE GRANULES
Field of the Invention This invention relates to the solution layering of pharmaceutically active drug on a predominately_ microcrystalline cellulose core.
Background of the Invention It is well known in the pharmaceutical art to apply a pharmaceutically active material to a smooth, spherical core. Typically, the process involves the application of a solution, suspension, or powder coating of the spherical_ core with the pharmaceutically active ingredient.
For example, Jones, D. M., in the chapter entitled, Solution and Suspension Layering, Pharmaceutical Pelletization Technoloay, describes layering a solution of drug onto seed material, generally a coarse crystal or nonpareil, in coating pans or fluidized bed equipment.
The chapter notes that the Wurster process can be used for coating and layering onto substrates as small as 100 microns, and coated layers of 100 to 150% of the starting batch weight may be applied. The author also notes that a binder is optional, but recommended, when applying drug from a solution.
Despite the teachings of the prior art, it is highly desirable to apply a pharmaceutically active material via solution coating that does not require a separate granulation step in order to increase the size of the substrate core prior to coating.
Sunnnary of the Invention The present invention is directed to a particle which comprises a seed core comprised predominately of microcrystalline cellulose, having an average particle size of about 180 microns, to which a pharmaceutically active ingredient in solution is layered onto the microcrystalline cellulose by spray coating. The seed core and the pharmaceutically active material is then overcoated with a suitable polymer. The mean particle = diameter of the final coated particle containing the pharmaceutically active ingredient and polymer is less than about 325 microns, which makes it smaller than traditional particles.
More specifically the present invention comprises a particle comprising a center core of predominately microcrystalline cellulose having an average particle size of about 160 to about 220 microns with a particle size standard deviation of from about 75 to about 200;
pharmaceutically active material coating the center core of microcrystalline cellulose;
wherein the coated particle is from about 40 to about 75 weight percent microcrystalline cellulose;
pharmaceutically active ingredient is from about 25 to about 60 weight percent; and a particle size of from about 200 to about 325 microns and a particle size standard deviation of from about 30 to about 175 microns.
The present invention also includes a method for making a pharmaceutically active particle comprising providing a center core of predominately microcrystalline cellulose having an average particle size of about 160 to about 220 microns with a particle size standard deviation of from about 75 to about 200;
coating said microcrystalline cellulose with a pharmaceutically active ingredient;
wherein the coated particle is from about 40 to about 75 weight percent microcrystalline cellulose; the pharmaceutically active ingredient is from about 25 to about 60 weight percent; and has a particle size of from about 200 to about 325 microns and a particle size standard deviation of from about 30 to about 175 microns; wherein the coating of the microcrystalline cellulose is performed in the absence of a granulation step.
According to one aspect of the present invention, there is provided a pharmaceutical composition comprising particles wherein each of the particles comprises: a center core of greater than 90 weight percent of microcrystalline cellulose having an average core size of 160 to 220 pm with a core size standard deviation of from 75 to 200 pm and having an irregular surface morphology and a non-spherical shape; and a pharmaceutically active material coating the center core of each particle; wherein each of the coated particles is from 40 to 75 weight percent microcrystalline cellulose; the pharmaceutically active material is from about 25 to 60 weight percent; and each coated particle has a particle size of from 200 to 325 pm and a particle size standard deviation of from 30 to 175 um.
According to another aspect of the present invention, there is provided a method for making a pharmaceutical composition comprising pharmaceutically active particles as described herein, wherein the coating of the microcrystalline cellulose is performed in the absence of a granulation step.
- 3a -Description of -the 'Drawinos Figure 1 is a photomicrograph of the preferred microcrystalline cellulose.
Figure 2 is a photomicrograph of the microcrystalline cellulose depicted in.F.igure 1 layered with a pharmaceutically active ingredient.
Figure 3 is a photomicrograph of the particles of the invention with a polymer coating.
Figure 4a and Figure 4b are photomicrographs of commercially available microcrystalline cellulose materials.
Detailed Description The seed core of the present invention is predominately microcrystalline cellulose. By predominately, it is understood that the seed core is greater than 90 weight percent, preferably greater than 95 weight percent and in a most preferred embodiment the seed core is entirely microcrystalline cellulose. Microcrystall.ine cellulose is uniquely well-suited as a substrate for film coating due to its surface characteristics, the abundance of free hydroxyl groups which improve film adhesion, and its insolubility which aids in processing. The preferred TM
source of microcrystalline cellulose is Avicel PH 200 available from FMC Corp. The preferred microcrystalline cellulose has a rough porous surface, a non-spherical shape, a median particle diameter of about 160 to about 220 microns and a narrow particle size distribution (standard deviation from about 75 to about 200 microns), with more than 50%, and preferably more than 60 percent of the particles between about 177 and about 300 microns.
Avicel PH200 has a nominal particle size of about 180 microns with a.low proportion of fines, less than 25% by weight of particles smal.ler than 125 microns.
In addition the microcrystalline cellulose should have a tapped bulk density of from about 0.40 to about 0.45 grams/cubic centimeters.
Another key characteristic of the preferred microcrystalline cellulose is the irregular shape of the surface of the microcrystalline cellulose. The microcrystalline cellulose.is preferably irregular in surface characteristics, see Figure 1. The irregular surface morphology provides porosity and allows the pharmaceutically active ingredient to be applied to the surface and to be adhered or retained on the surface, see Figure 2, pseudoephedrine hydrochloride, dextromethorphan hydrobromide, and chlorpheniramine maleate layered on the microcrystalline cellulose surface, see Example 1 below..
Surprisingly we have found that the irregular surface morphology of the preferred microcrystalline cellulose provides a better surface to layer the pharmaceutically active material than other microcrystalline cellulose products sold for this purpose, which have a more smooth surface and higher degree o.f sphericity see Figures 4a and 4b, Celphere 203 and 102(FMC Corp.), depicted in Figures 4a and 4b respectively.
Greater surface porosity on the microcrystalline cellulose allows the pharmaceutically active material to be layered or adsorbed with minimal effect on flowability.
Better flow leads to superior blend homogeneity and tablet content uniformity, which are critical quality aspects of the process and product. Commercially available products such as Celphere 203 and 102(FMC Corp.), are regular, spherical particles, having aspect ratios of about 1, which also lack the desired surface characteristics.
Field of the Invention This invention relates to the solution layering of pharmaceutically active drug on a predominately_ microcrystalline cellulose core.
Background of the Invention It is well known in the pharmaceutical art to apply a pharmaceutically active material to a smooth, spherical core. Typically, the process involves the application of a solution, suspension, or powder coating of the spherical_ core with the pharmaceutically active ingredient.
For example, Jones, D. M., in the chapter entitled, Solution and Suspension Layering, Pharmaceutical Pelletization Technoloay, describes layering a solution of drug onto seed material, generally a coarse crystal or nonpareil, in coating pans or fluidized bed equipment.
The chapter notes that the Wurster process can be used for coating and layering onto substrates as small as 100 microns, and coated layers of 100 to 150% of the starting batch weight may be applied. The author also notes that a binder is optional, but recommended, when applying drug from a solution.
Despite the teachings of the prior art, it is highly desirable to apply a pharmaceutically active material via solution coating that does not require a separate granulation step in order to increase the size of the substrate core prior to coating.
Sunnnary of the Invention The present invention is directed to a particle which comprises a seed core comprised predominately of microcrystalline cellulose, having an average particle size of about 180 microns, to which a pharmaceutically active ingredient in solution is layered onto the microcrystalline cellulose by spray coating. The seed core and the pharmaceutically active material is then overcoated with a suitable polymer. The mean particle = diameter of the final coated particle containing the pharmaceutically active ingredient and polymer is less than about 325 microns, which makes it smaller than traditional particles.
More specifically the present invention comprises a particle comprising a center core of predominately microcrystalline cellulose having an average particle size of about 160 to about 220 microns with a particle size standard deviation of from about 75 to about 200;
pharmaceutically active material coating the center core of microcrystalline cellulose;
wherein the coated particle is from about 40 to about 75 weight percent microcrystalline cellulose;
pharmaceutically active ingredient is from about 25 to about 60 weight percent; and a particle size of from about 200 to about 325 microns and a particle size standard deviation of from about 30 to about 175 microns.
The present invention also includes a method for making a pharmaceutically active particle comprising providing a center core of predominately microcrystalline cellulose having an average particle size of about 160 to about 220 microns with a particle size standard deviation of from about 75 to about 200;
coating said microcrystalline cellulose with a pharmaceutically active ingredient;
wherein the coated particle is from about 40 to about 75 weight percent microcrystalline cellulose; the pharmaceutically active ingredient is from about 25 to about 60 weight percent; and has a particle size of from about 200 to about 325 microns and a particle size standard deviation of from about 30 to about 175 microns; wherein the coating of the microcrystalline cellulose is performed in the absence of a granulation step.
According to one aspect of the present invention, there is provided a pharmaceutical composition comprising particles wherein each of the particles comprises: a center core of greater than 90 weight percent of microcrystalline cellulose having an average core size of 160 to 220 pm with a core size standard deviation of from 75 to 200 pm and having an irregular surface morphology and a non-spherical shape; and a pharmaceutically active material coating the center core of each particle; wherein each of the coated particles is from 40 to 75 weight percent microcrystalline cellulose; the pharmaceutically active material is from about 25 to 60 weight percent; and each coated particle has a particle size of from 200 to 325 pm and a particle size standard deviation of from 30 to 175 um.
According to another aspect of the present invention, there is provided a method for making a pharmaceutical composition comprising pharmaceutically active particles as described herein, wherein the coating of the microcrystalline cellulose is performed in the absence of a granulation step.
- 3a -Description of -the 'Drawinos Figure 1 is a photomicrograph of the preferred microcrystalline cellulose.
Figure 2 is a photomicrograph of the microcrystalline cellulose depicted in.F.igure 1 layered with a pharmaceutically active ingredient.
Figure 3 is a photomicrograph of the particles of the invention with a polymer coating.
Figure 4a and Figure 4b are photomicrographs of commercially available microcrystalline cellulose materials.
Detailed Description The seed core of the present invention is predominately microcrystalline cellulose. By predominately, it is understood that the seed core is greater than 90 weight percent, preferably greater than 95 weight percent and in a most preferred embodiment the seed core is entirely microcrystalline cellulose. Microcrystall.ine cellulose is uniquely well-suited as a substrate for film coating due to its surface characteristics, the abundance of free hydroxyl groups which improve film adhesion, and its insolubility which aids in processing. The preferred TM
source of microcrystalline cellulose is Avicel PH 200 available from FMC Corp. The preferred microcrystalline cellulose has a rough porous surface, a non-spherical shape, a median particle diameter of about 160 to about 220 microns and a narrow particle size distribution (standard deviation from about 75 to about 200 microns), with more than 50%, and preferably more than 60 percent of the particles between about 177 and about 300 microns.
Avicel PH200 has a nominal particle size of about 180 microns with a.low proportion of fines, less than 25% by weight of particles smal.ler than 125 microns.
In addition the microcrystalline cellulose should have a tapped bulk density of from about 0.40 to about 0.45 grams/cubic centimeters.
Another key characteristic of the preferred microcrystalline cellulose is the irregular shape of the surface of the microcrystalline cellulose. The microcrystalline cellulose.is preferably irregular in surface characteristics, see Figure 1. The irregular surface morphology provides porosity and allows the pharmaceutically active ingredient to be applied to the surface and to be adhered or retained on the surface, see Figure 2, pseudoephedrine hydrochloride, dextromethorphan hydrobromide, and chlorpheniramine maleate layered on the microcrystalline cellulose surface, see Example 1 below..
Surprisingly we have found that the irregular surface morphology of the preferred microcrystalline cellulose provides a better surface to layer the pharmaceutically active material than other microcrystalline cellulose products sold for this purpose, which have a more smooth surface and higher degree o.f sphericity see Figures 4a and 4b, Celphere 203 and 102(FMC Corp.), depicted in Figures 4a and 4b respectively.
Greater surface porosity on the microcrystalline cellulose allows the pharmaceutically active material to be layered or adsorbed with minimal effect on flowability.
Better flow leads to superior blend homogeneity and tablet content uniformity, which are critical quality aspects of the process and product. Commercially available products such as Celphere 203 and 102(FMC Corp.), are regular, spherical particles, having aspect ratios of about 1, which also lack the desired surface characteristics.
5 Until now it has been widely believed that smooth spherical particles were the best substrates for coating.
US Patent 5,384,130, 5,505,983 disclose the disadvantages of using sugar spheres, especially for aqueous layering processes, since they dissolve readily in water leading to agglomeration, and provide a more highly friable coated particle subject to fracture. Fracture of the particle coating compromises it's functionality, whether it is used for the purpose of controlled release, or tastemasking. Generally, substrates used for particle coating are prepared by rotor-granulation or other agglomeration processes to achieve.a average particle size of at least about 250 microns. The size a.f substrate which may be successfully coated without unwanted agglomeration of particles has previously been limited by the size of droplets which may be obtained from the available atomizing spray guns. Zmprovements in spray gun technology have lead to smaller droplet sizes, allowing for the successful coating of smaller substrates. -Another benefit of the preferred microcrystalline cellulose is the narrow particle size distribution associated with the microcrystalline cellulose and the particles which contain the pharmaceutically active material. The particle size standard deviation is a term that is understood in the art, see Lachman L., Lieberman H., Pharmaceutical Dosage Forms: Tablets jV2), Dekker Inc, NY, 1981, pages 185-202, and is a measure of the homogeneity of the particles with respect to particle size.. The present invention employs microcrystalline celluloses with a particle size standard deviation of from about 75 to about 200 microns, preferably from about 80 to about 150; and most preferably from about 85 to about 95 microns.
Solution layering of the pharmaceutically active material requires that the pharmaceutically active = material is first dissolved in a solvent and is then sprayed onto the surface of the microcrystalline cellulose.
Preferably the solvent is water, however other pharmaceutically acceptable solvents may also be employed including, but not limited to, methanol acetone and mixtures thereof. The selection of solvent is based upon the pharmaceutically active material that is to be layered onto the core particle.
The pharmaceutically active material to be applied to the microcrystalline cellulose core is not critical as long as it is dissolved in the solvent. The use of pharmaceutically active materials provided within a suspension or a dispersion are also provided within the scope of the invention provided that pharmaceutically acceptable suspending or emulsifing agents are employed.
The pharmaceutically active ingredient must be soluble in an acceptable solvent so that it can be applied to the core particle. Suitable active ingredients include pharmaceuticals, minerals, vitamins and other nutraceuticals. Suitable pharmacuticals include but are not limited to analgesics, decongestants, expectorants, antitussives, antihistamines, gastrointestinal agents, diuretics, bronchodilators, sleep-inducing agents and mixtures thereof. Preferred pharmaceutical active ingredients for solution layering include pseudoephedrine, phenylpropanolamine, chlorpheniramine, dextromethorphan, diphenhydramine, doxylamine, loperamide, mixtures thereof and pharmaceutically acceptable salts thereof. Preferred - ~ -pharmaceutical active ingredients for suspension layering include acetaminophen, ibuprofen, flurbiprofen, naproxen, aspirin, famotidine, .loperamide, ranitidine, c.imetidine, astemizole, terfenadine, terfenadine carboxylate, loratadine, cetirizine, mixtures thereof and pharmaceutically acceptable salts thereof.
The weight percent of the pharmaceutically active ingredient in the solution is typically in the range of from about 5 to 75, preferably from about 40 to about 60 and most preferably about 45 to about 56 weight percent in the solution. The solution is sprayed onto the surface of the microcrystalline cellulose, preferably by the use of rotor or Wurster coating. These processes as well as other suitable methods are known in the art.
The amount of drug active to be layered onto the substrate particles is determined by the desired dose in the finished product.
If the active ingredient has an objectionable taste, or if controlled release is desired, the particle containing the active ingredient may be coated with a polymer system, 70/30 mixture of cellulose acetate and EUDRAGIT E 100 (see Figure 3). The active may be coated with coatings known in the art, such as those described in U.S. Patent Nos.
4,851,226, 5,075,114, and 5,489,436. The coating may provide for immediate or sustained release of the active.
- $ -Suitable coating compositions, include but are not limited to the coatings provided in the following table:
Polvmer System Coat Levell Polvmer Ratio2 Cellulose Acetate/PVP 5-60% 90/10 to 60/40 Cellulose Acetate Butyrate/PVP 5-60% 90/10 to 60/40 Cellulose Acetate/HPC 5-60% 90/10 to 50/50 Cellulose Acetate Butyrate/HPC 5-60% 90/10-to 50/50 Cellulose Acetate/
EUDRAGIT E100 8-60% All ratios Cellulose Acetate Butyrate/
EUDRAGIT E 100 8-60$ All ratios Ethyl Cellulose/PVP 8-60$ 90/10 to 60/40 Ethyl Cellulose/HPC 8-60% 90/10 to 50/50 Ethyl Cellulose/EUDRAGIT
E 100 8-60% All ratios HPC 10-60% NA
HEC 10-60% NA
EUDRAGIT E 100 10-60% NA
HPMC 10-60% NA
HEC/HPMC 10-60% All ratios HPC/HPMC 10-60% All ratios HEC/HPC 10-60% All ratios 2-vinyl pyrridine styrene co-polymer 10-60% NA
CA/2-vps 8-60% All ratios CAB/2-vps 8-60% All ratios Ethyl Cellulose/2-vps 8-60% All ratios Cellulose Triacetate/PVP 8-60%90/10 to 60/40 Cellulose Triacetate/HPC 8-60%90/10 to 50/50 Cellulose Triacetate/
EUDRAGIT E 100 8-60% All ratios Percent by weight of the coated particle in a dried itate.
By weight.
PVP polyvinylpyrrolidone; HPC Hydroxypropyl cellulose HEC - Hydroxyethyl cellulose; HPMC - Hydroxypropylmethyl cellulose; CA - Cellulose Acetate CAB - Cellulose Acetate Butyrate 2-VPS - 2-Vinyl pyridine styrene EUDRAGITT"' E-100 - methylaminoethyl-methacrylate and neutral methacrylic acid esters available from Rohm Pharma GmbH, Germany.
The final particle comprises an inactive core particle, the pharmaceutically active drug layered onto the core and the optional polymer coating. The drug active loaded on to the microcrystalline cellulose is typically present at a level of from about 10 to about 75 weight percent, preferably from about 25 to about 60 weight percent and most preferably from about 30 to about 50 weight percent of the weight of the final drug-layered coated particle.
The present invention is an improvement over the prior art in that the particle size distribution of the coated particles is narrower than the particles previously made. The narrower distribution of particle size is a result of the preferred starting material and the absence of an agglomeration step to form the core prior to drug layering onto the particles. The prior art discloses the granulation or agglomeration of the inactive core particles which are then layered with drug and coated.
This results in a wider distribution of particle size, which provides a gritty texture in the mouth. The present invention provides a smaller particle with a narrower distribution of particle size, which results in a less gritty texture/mouthfeel.
The drug layered particle size distribution is narrower than for other processes, said standard deviation ranging from about 30 to about 175 microns, more preferably from about 65 to about 120, and most preferably from about 75 to about 100 microns.
Because the final particles are also smaller than those previous disclosed, and there is a polymeric coating covering the pharmaceutically active materials, the particles have a plastic coating which is difficult to fracture. This coating provides a pleasant taste which makes them particularly well suited for a chewable tablet.
v A further advantage is the elimination of the granulation step in the manufacturing method. These benefits are accomplished without the agglomeration and flow problems previously encountered. A further advantage is because the granulation step is avoided, the size distribution of the particles is more narrow than with traditional methods. This provides improved flow characteristics as well as avoiding fines which cause unwanted agglomeration during the process or plugging of process equipment. Narrow size distribution of the substrate for drug layering or further polymer coating is also a processing advantage, reducing agglomeration due to sticking of small particles to larger particles.
A further advantage of the present invention is the flexibility of the process. The present invention can be used to apply coatings which can include extended release, time release, enteric coatings and the like.
In addition to the microcrystalline cellulose in the core, additional excipients can be added to the core, including but not limited to lactose, starches, mannitol and the like. Typically the excipients are less than about 10 percent by weight of the final product. The inclusion of these excipients is not preferred since they tend to increase the particle size distribution of the coated product.
After the coated particles are formed, the particles are then combined with excipients well known in the art, and compressed to provide a capsule or tablet.
The following examples are provided to further illustrate the claimed invention, but not limit the invention to the examples provided below. Unless noted to the contrary, all parts are parts by weight.
~
Example 1: Drug-layered particles This example provides a formulation and process for making a drug-coated particle which is suitable for use as a substrate for further particle coating with any of a number of polymers or polymer combinations. In this example, the particle contains three active ingredients.
= Single active ingredient particles may be prepared by a similar method. Unless otherwise noted, all parts are understood to be parts by weight.
An aqueous solution was prepared, containing the following ingredients (total weight 3.03 kg):
Pseudoephedrine Hydrochloride 15 parts Dextromethorphan Hydrobromide 5 parts Chlorpheniramine Maleate 1 part Polyvinyl Pyrrolidone 2.27 (K29/32) parts Purified Water 22.8 parts Microcrystalline cellulose (Avicel 200, 3.47 kg) was charged into a fluidized bed coating apparatus (Glatt Model GPCG 5/9). The microcrystalline cellulose was then fluidized by a flow of air at an inlet temperature of 46 C.
The drug-containing layering solution was then sprayed onto the fluidized microcrystalline cellulose particles at a rate of 65 grams/min. until coated microcrystalline cellulose particles containing approximately 31% by weight of the.
drug-containing coating were obtained. Particle Size Distribution of microcrystalline cellulose start ng material(based on normal distribution model):
Median: 213 microns, Standard deviation: 191 microns Size distributinr, of drug-layered particles 4w (based on normal distribution model):
Median: 293 microns, Standard deviation: 160 microns Assav Results The drug-layered particles in this example were found to have drug potencies of 23.6% pseudoephedrine hydrochloride, 6.72% dextromethorphan hydrobromide, and = 1.36% chlorpheniramine maleate.
Example 2: Pseudoephedrine layered Avicel PH2O0 with PVP
This example provides a formulation and process for making a drug-coated particle which is suitable for use as a substrate for further particle coating with any of a number of polymers or polymer combinations. In this example, the particle contains pseudoephedrine hydrochloride as the active ingredient, with polyvinyl pyrrolidone as the binder.
An aqueous solution was prepared, containing the following ingredients (total weight 3.62 kg):
Pseudoephedrine Hydrochloride 55.3$
Polyvinyl Pyrrolidone 1.1%
(K29/32) Purified Water 43.6%
Microcrystalline cellulose (Avicel 200, 1.96 kg) was charged into a Rotor (tangential spray) fluidized bed coating apparatus (Glatt Model GPCG 5/9). The microcrystalline cellulose was then fluidized by a flow of air at an inlet temperature of 36 C. The drug-containing layering solution was then sprayed onto the fluidized microcrystalline cellulose particles at a rate of 80 grams/min. until coated microcrystalline cellulose particles containing approximately 50% by weight of the drug-containing coating were obtained.
~
Size distribution of drug-layered particles:
(based on normal distribution model):
Median: 238 microns, Standard deviation: 77 microns Example 3: Tastemasked coated drug-layered tiarticles This example provides a formulation and process for further coating the drug layered particles in example 2 with polymer for tastemasking. In this example, the tastemasking polymer system was a combination of cellulose acetate and Eudragit E-100. Tastemasked coated particles may be prepared by a similar method, using other polymer systems.
A solution was prepared, containing Cellulose Acetate 398-10 (Eastman Chemical) and Eudragit E-100 (Rohm Pharma) at a level of 12% solids in acetone (total weight 10.7 kg). The ratio of cellulose acetate to Eudragit E-100 was 95:5. A portion (3.0 kg) of the drug layered particles produced in Example 2 was charged into a rotor (tangential spray) fluidized bed coating apparatus (Glatt Model GPCG
5/9). The drug-layered particles were then fluidized by a flow of air at an inlet temperature of 36 C. The polymer coating solution was then sprayed onto the fluidized particles at a rate of 40 grams/min. until coated drug particles containing approximately 30% by weight of the polymer coating were obtained.
Size distribution of tiolvmer-coated. drua-layered Rarticles (based on normal distribution model):
Median: 283 microns, Standard deviation: 84 microns ~
Examnle 4: Diphenhvdramine layered Avicel PH200 (no binder used) This example provides a formulation and process for making a drug-coated particle which is suitable for use as a substrate for further particle coating with any of a number of polymers or polymer combinations. In this = example, the particle contains diphenhydramine as the active ingredient, with no added binder.
An aqueous solution was prepared, containing the following ingredients (total weight 3.58 kg):
Diphenhydramine 56%
Purified Water 44%
Microcrystalline cellulose (Avicel 200, 2.0 kg) was charged into a Rotor (tangential spray) fluidized bed coating apparatus (Glatt Model GPCG 5/9). The microcrystalline cellulose was then fluidized by a flow of air at an inlet temperature of 38 C. The drug-containing layering solution was then sprayed onto the fluidized microcrystalline cellulose particles at a rate of 30 grams/minutes until coated microcrystalline cellulose particles containing approximately 50% by weight of the drug-containing coating were obtained.
Size distribution of drug-lavered particles=
(based on normal distribution model):
Median: 302 microns, Standard deviation: 94 microns Flow analysis demonstrated this material remained free-flowing after 4 days at 40 C / 75% RH. (open dish) . . ~
Examule 5: Tastemasked coated drug-layered particles This example provides a formulation and process for further coating the drug layered particles in example 4 with polymer for tastemasking. In this example, the tastemasking polymer system is a combination of cellulose acetate and Eudragit E-100. Tastemasked coated particles may be prepared by a similar method, using other polymer systems.
A solution was prepared, containing Cellulose Acetate 398-10 and Eudragit E-100 at a level of 12% solids in Acetone (total weight 10.7 kg). The ratio of cellulose acetate to Eudragit E-100 was 95:5.
A portion (3.0 kg) of the drug layered particles produced in example 2 was charged into a Rotor (tangential spray) fluidized bed coating apparatus (Glatt Model GPCG
5/9). The drug-layered particles were then fluidized by a flow of air at an inlet temperature of 36 C. The polymer coating solution was then sprayed onto the fluidized particles at a rate of 35 grams/min. until coated drug particles containing approximately 30% by weight of the polymer coating were obtained.
Size distribution of polymer-coated drug-layered particles (based on normal distribution model):
Median: 309 microns, Standard deviation: 91 microns ~
Ex mple 6 IChewable Tabletsl Tastemasked coated diphenhydramine particles, and tastemasked coated pseudoephedrine hydrochloride particles, prepared in the manner described above, were combined with tastemasked acetaminophen particles (prepared according to methods disclosed in US Patent Number 4,851,226) and the following inactive ingredients to produce chewable tablets, using the process described below:
Material Quantity (mg/
tablet) CA/PVP Coated Acetaminophen (89% potent) 90.91 CA/E100 Coated Pseudoephedrine 21.43 Hydrochloride (35% potent) CA/E100 Coated Diphenhydramine 17.86 Hydrochloride (35% potent) -Mannitol USP (Granular) 284.56 Microcrystalline Cellulose NF 36.0 Aspartame NF 9.6 Flavor 14.6 Color (lakes) 0.24 Magnesium Stearate NF 4.8 Tablet Weight 480 a. All ingredients except magnesium stearate were combined in a PK blender, and blended for 25 minutes. The magnesium stearate was to the blender and blending was continued for an additional 5 minutes.
~
b. Tablets were compressed to the following specifications on a Manesty Betapress using 13/32-inch diameter, round flat-faced beveled edge tooling:
Taraet Weight (mg: average of 10) 480 Thickness (mm: average of 5) 4.8 Hardness (kp: average of 5) 6.0 Friability (% loss: 20 tablets) < 1.0 Resulting tablets had good taste characteristics with minimal bitterness.
Comparative ExamDle 1 Celphere 203 This example provides a formulation and process for layering diphenhydramine onto Celphere 203 (FMC Corp.) a commercially available product marketed as an ideal substrate for drug-layering and particle coating.
A.) An aqueous solution was prepared, containing the following ingredients (total weight 2.68 kg):
Diphenhydramine 56%
Purified Water 44%
Microcrystalline cellulose (Celphere 203, 1.5 kg) was charged into a Rotor (tangential spray) fluidized bed coating apparatus (Glatt Model GPCG 5/9). The Microcrystalline cellulose was then fluidized by a flow of air at an inlet temperature of 34 C. The drug-containing layering solution was then sprayed onto the fluidized Microcrystalline cellulose particles at a rate of 20 grams/min. until coated Microcrystalline cellulose particles containing approximately 50% by weight of the drug-containing coating were obtained.
Flow analysis demonstrated this material became sticky and not free-flowing after 4 days at 40 C / 75% Relative Humidity. (open dish) B.) The drug layered particles were further coated with polymer for tastemasking. In this example, the tastemasking polymer system is a combination of cellulose acetate and Eudragit E-100. A solution was prepared, containing Cellulose Acetate 398-10 and Eudragit E-100 at a level of 12% solids in Acetone (total weight 3.3 kg).
The ratio of cellulose acetate to Eudragit E-100 was 70:30.
A portion (1.0 kg) of the drug layered particles produced in part A was charged into a Rotor (tangential spray) fluidized bed coating apparatus (Glatt Model GPCG
5/9). The drug-layered particles were then fluidized by a flow of air at an inlet temperature of 32 C. The polymer coating solution was then sprayed onto the fluidized particles at a rate of 20 grams/min. until coated drug particles containing approximately 30% by weight of the polymer coating were obtained.
Size distribution of drug-layered particles:
(based on normal distribution model):
Median: 373 microns, Standard deviation: 84 microns Size distribution of polymer-coated, drug-lavered particles (based on normal distribution model):
Median: 399 microns, Standard deviation: 83 microns Comuarative Examole 2 Lactose granules with Methocel E5 (Dow) binder were used as a substrate for layering pseudoephedrine hydrochloride and dextromethorphan hydrobormide, then coating with CA:E100 at a 60 $ level. Resulting tablets were gritty (due to large particle size) and slow to dissolve (due to 60% coating level).
Comparative Example 3 Avicel PH101 (FMC Corp.) was rotor granulated together with pseudoephedrine hydrochloride, dextromethorphan hydrobromide, and chlorpheniramine maleate. Resulting product had median diameter of 51 microns with standard deviation of 270 microns. A high degree of agglomeration and a high degree of fine particles were observed visually.
Comparative Exam lpe 4 Direct coating of the individual (psedoephedrine and i5 diphenhydramine) active particles was attempted, but not pursued further due to excessive agglomeration and poor tastemasking.
Comparative Example 5 Granulating amines (pseudoephedrine and diphenhydramine) together with powdered acetaminophen using water or hydroxypropyl methyl cellulose binder solution was attempted, but not pursued due to a eutectic mixture formation between diphenhydramine and the other ingredients. Moisture adsorption studies suggested that pseudoephedrine and diphenhydramine undergo a solid state interaction at relative humidities > 75% resulting in formation of a deliquescent material.
US Patent 5,384,130, 5,505,983 disclose the disadvantages of using sugar spheres, especially for aqueous layering processes, since they dissolve readily in water leading to agglomeration, and provide a more highly friable coated particle subject to fracture. Fracture of the particle coating compromises it's functionality, whether it is used for the purpose of controlled release, or tastemasking. Generally, substrates used for particle coating are prepared by rotor-granulation or other agglomeration processes to achieve.a average particle size of at least about 250 microns. The size a.f substrate which may be successfully coated without unwanted agglomeration of particles has previously been limited by the size of droplets which may be obtained from the available atomizing spray guns. Zmprovements in spray gun technology have lead to smaller droplet sizes, allowing for the successful coating of smaller substrates. -Another benefit of the preferred microcrystalline cellulose is the narrow particle size distribution associated with the microcrystalline cellulose and the particles which contain the pharmaceutically active material. The particle size standard deviation is a term that is understood in the art, see Lachman L., Lieberman H., Pharmaceutical Dosage Forms: Tablets jV2), Dekker Inc, NY, 1981, pages 185-202, and is a measure of the homogeneity of the particles with respect to particle size.. The present invention employs microcrystalline celluloses with a particle size standard deviation of from about 75 to about 200 microns, preferably from about 80 to about 150; and most preferably from about 85 to about 95 microns.
Solution layering of the pharmaceutically active material requires that the pharmaceutically active = material is first dissolved in a solvent and is then sprayed onto the surface of the microcrystalline cellulose.
Preferably the solvent is water, however other pharmaceutically acceptable solvents may also be employed including, but not limited to, methanol acetone and mixtures thereof. The selection of solvent is based upon the pharmaceutically active material that is to be layered onto the core particle.
The pharmaceutically active material to be applied to the microcrystalline cellulose core is not critical as long as it is dissolved in the solvent. The use of pharmaceutically active materials provided within a suspension or a dispersion are also provided within the scope of the invention provided that pharmaceutically acceptable suspending or emulsifing agents are employed.
The pharmaceutically active ingredient must be soluble in an acceptable solvent so that it can be applied to the core particle. Suitable active ingredients include pharmaceuticals, minerals, vitamins and other nutraceuticals. Suitable pharmacuticals include but are not limited to analgesics, decongestants, expectorants, antitussives, antihistamines, gastrointestinal agents, diuretics, bronchodilators, sleep-inducing agents and mixtures thereof. Preferred pharmaceutical active ingredients for solution layering include pseudoephedrine, phenylpropanolamine, chlorpheniramine, dextromethorphan, diphenhydramine, doxylamine, loperamide, mixtures thereof and pharmaceutically acceptable salts thereof. Preferred - ~ -pharmaceutical active ingredients for suspension layering include acetaminophen, ibuprofen, flurbiprofen, naproxen, aspirin, famotidine, .loperamide, ranitidine, c.imetidine, astemizole, terfenadine, terfenadine carboxylate, loratadine, cetirizine, mixtures thereof and pharmaceutically acceptable salts thereof.
The weight percent of the pharmaceutically active ingredient in the solution is typically in the range of from about 5 to 75, preferably from about 40 to about 60 and most preferably about 45 to about 56 weight percent in the solution. The solution is sprayed onto the surface of the microcrystalline cellulose, preferably by the use of rotor or Wurster coating. These processes as well as other suitable methods are known in the art.
The amount of drug active to be layered onto the substrate particles is determined by the desired dose in the finished product.
If the active ingredient has an objectionable taste, or if controlled release is desired, the particle containing the active ingredient may be coated with a polymer system, 70/30 mixture of cellulose acetate and EUDRAGIT E 100 (see Figure 3). The active may be coated with coatings known in the art, such as those described in U.S. Patent Nos.
4,851,226, 5,075,114, and 5,489,436. The coating may provide for immediate or sustained release of the active.
- $ -Suitable coating compositions, include but are not limited to the coatings provided in the following table:
Polvmer System Coat Levell Polvmer Ratio2 Cellulose Acetate/PVP 5-60% 90/10 to 60/40 Cellulose Acetate Butyrate/PVP 5-60% 90/10 to 60/40 Cellulose Acetate/HPC 5-60% 90/10 to 50/50 Cellulose Acetate Butyrate/HPC 5-60% 90/10-to 50/50 Cellulose Acetate/
EUDRAGIT E100 8-60% All ratios Cellulose Acetate Butyrate/
EUDRAGIT E 100 8-60$ All ratios Ethyl Cellulose/PVP 8-60$ 90/10 to 60/40 Ethyl Cellulose/HPC 8-60% 90/10 to 50/50 Ethyl Cellulose/EUDRAGIT
E 100 8-60% All ratios HPC 10-60% NA
HEC 10-60% NA
EUDRAGIT E 100 10-60% NA
HPMC 10-60% NA
HEC/HPMC 10-60% All ratios HPC/HPMC 10-60% All ratios HEC/HPC 10-60% All ratios 2-vinyl pyrridine styrene co-polymer 10-60% NA
CA/2-vps 8-60% All ratios CAB/2-vps 8-60% All ratios Ethyl Cellulose/2-vps 8-60% All ratios Cellulose Triacetate/PVP 8-60%90/10 to 60/40 Cellulose Triacetate/HPC 8-60%90/10 to 50/50 Cellulose Triacetate/
EUDRAGIT E 100 8-60% All ratios Percent by weight of the coated particle in a dried itate.
By weight.
PVP polyvinylpyrrolidone; HPC Hydroxypropyl cellulose HEC - Hydroxyethyl cellulose; HPMC - Hydroxypropylmethyl cellulose; CA - Cellulose Acetate CAB - Cellulose Acetate Butyrate 2-VPS - 2-Vinyl pyridine styrene EUDRAGITT"' E-100 - methylaminoethyl-methacrylate and neutral methacrylic acid esters available from Rohm Pharma GmbH, Germany.
The final particle comprises an inactive core particle, the pharmaceutically active drug layered onto the core and the optional polymer coating. The drug active loaded on to the microcrystalline cellulose is typically present at a level of from about 10 to about 75 weight percent, preferably from about 25 to about 60 weight percent and most preferably from about 30 to about 50 weight percent of the weight of the final drug-layered coated particle.
The present invention is an improvement over the prior art in that the particle size distribution of the coated particles is narrower than the particles previously made. The narrower distribution of particle size is a result of the preferred starting material and the absence of an agglomeration step to form the core prior to drug layering onto the particles. The prior art discloses the granulation or agglomeration of the inactive core particles which are then layered with drug and coated.
This results in a wider distribution of particle size, which provides a gritty texture in the mouth. The present invention provides a smaller particle with a narrower distribution of particle size, which results in a less gritty texture/mouthfeel.
The drug layered particle size distribution is narrower than for other processes, said standard deviation ranging from about 30 to about 175 microns, more preferably from about 65 to about 120, and most preferably from about 75 to about 100 microns.
Because the final particles are also smaller than those previous disclosed, and there is a polymeric coating covering the pharmaceutically active materials, the particles have a plastic coating which is difficult to fracture. This coating provides a pleasant taste which makes them particularly well suited for a chewable tablet.
v A further advantage is the elimination of the granulation step in the manufacturing method. These benefits are accomplished without the agglomeration and flow problems previously encountered. A further advantage is because the granulation step is avoided, the size distribution of the particles is more narrow than with traditional methods. This provides improved flow characteristics as well as avoiding fines which cause unwanted agglomeration during the process or plugging of process equipment. Narrow size distribution of the substrate for drug layering or further polymer coating is also a processing advantage, reducing agglomeration due to sticking of small particles to larger particles.
A further advantage of the present invention is the flexibility of the process. The present invention can be used to apply coatings which can include extended release, time release, enteric coatings and the like.
In addition to the microcrystalline cellulose in the core, additional excipients can be added to the core, including but not limited to lactose, starches, mannitol and the like. Typically the excipients are less than about 10 percent by weight of the final product. The inclusion of these excipients is not preferred since they tend to increase the particle size distribution of the coated product.
After the coated particles are formed, the particles are then combined with excipients well known in the art, and compressed to provide a capsule or tablet.
The following examples are provided to further illustrate the claimed invention, but not limit the invention to the examples provided below. Unless noted to the contrary, all parts are parts by weight.
~
Example 1: Drug-layered particles This example provides a formulation and process for making a drug-coated particle which is suitable for use as a substrate for further particle coating with any of a number of polymers or polymer combinations. In this example, the particle contains three active ingredients.
= Single active ingredient particles may be prepared by a similar method. Unless otherwise noted, all parts are understood to be parts by weight.
An aqueous solution was prepared, containing the following ingredients (total weight 3.03 kg):
Pseudoephedrine Hydrochloride 15 parts Dextromethorphan Hydrobromide 5 parts Chlorpheniramine Maleate 1 part Polyvinyl Pyrrolidone 2.27 (K29/32) parts Purified Water 22.8 parts Microcrystalline cellulose (Avicel 200, 3.47 kg) was charged into a fluidized bed coating apparatus (Glatt Model GPCG 5/9). The microcrystalline cellulose was then fluidized by a flow of air at an inlet temperature of 46 C.
The drug-containing layering solution was then sprayed onto the fluidized microcrystalline cellulose particles at a rate of 65 grams/min. until coated microcrystalline cellulose particles containing approximately 31% by weight of the.
drug-containing coating were obtained. Particle Size Distribution of microcrystalline cellulose start ng material(based on normal distribution model):
Median: 213 microns, Standard deviation: 191 microns Size distributinr, of drug-layered particles 4w (based on normal distribution model):
Median: 293 microns, Standard deviation: 160 microns Assav Results The drug-layered particles in this example were found to have drug potencies of 23.6% pseudoephedrine hydrochloride, 6.72% dextromethorphan hydrobromide, and = 1.36% chlorpheniramine maleate.
Example 2: Pseudoephedrine layered Avicel PH2O0 with PVP
This example provides a formulation and process for making a drug-coated particle which is suitable for use as a substrate for further particle coating with any of a number of polymers or polymer combinations. In this example, the particle contains pseudoephedrine hydrochloride as the active ingredient, with polyvinyl pyrrolidone as the binder.
An aqueous solution was prepared, containing the following ingredients (total weight 3.62 kg):
Pseudoephedrine Hydrochloride 55.3$
Polyvinyl Pyrrolidone 1.1%
(K29/32) Purified Water 43.6%
Microcrystalline cellulose (Avicel 200, 1.96 kg) was charged into a Rotor (tangential spray) fluidized bed coating apparatus (Glatt Model GPCG 5/9). The microcrystalline cellulose was then fluidized by a flow of air at an inlet temperature of 36 C. The drug-containing layering solution was then sprayed onto the fluidized microcrystalline cellulose particles at a rate of 80 grams/min. until coated microcrystalline cellulose particles containing approximately 50% by weight of the drug-containing coating were obtained.
~
Size distribution of drug-layered particles:
(based on normal distribution model):
Median: 238 microns, Standard deviation: 77 microns Example 3: Tastemasked coated drug-layered tiarticles This example provides a formulation and process for further coating the drug layered particles in example 2 with polymer for tastemasking. In this example, the tastemasking polymer system was a combination of cellulose acetate and Eudragit E-100. Tastemasked coated particles may be prepared by a similar method, using other polymer systems.
A solution was prepared, containing Cellulose Acetate 398-10 (Eastman Chemical) and Eudragit E-100 (Rohm Pharma) at a level of 12% solids in acetone (total weight 10.7 kg). The ratio of cellulose acetate to Eudragit E-100 was 95:5. A portion (3.0 kg) of the drug layered particles produced in Example 2 was charged into a rotor (tangential spray) fluidized bed coating apparatus (Glatt Model GPCG
5/9). The drug-layered particles were then fluidized by a flow of air at an inlet temperature of 36 C. The polymer coating solution was then sprayed onto the fluidized particles at a rate of 40 grams/min. until coated drug particles containing approximately 30% by weight of the polymer coating were obtained.
Size distribution of tiolvmer-coated. drua-layered Rarticles (based on normal distribution model):
Median: 283 microns, Standard deviation: 84 microns ~
Examnle 4: Diphenhvdramine layered Avicel PH200 (no binder used) This example provides a formulation and process for making a drug-coated particle which is suitable for use as a substrate for further particle coating with any of a number of polymers or polymer combinations. In this = example, the particle contains diphenhydramine as the active ingredient, with no added binder.
An aqueous solution was prepared, containing the following ingredients (total weight 3.58 kg):
Diphenhydramine 56%
Purified Water 44%
Microcrystalline cellulose (Avicel 200, 2.0 kg) was charged into a Rotor (tangential spray) fluidized bed coating apparatus (Glatt Model GPCG 5/9). The microcrystalline cellulose was then fluidized by a flow of air at an inlet temperature of 38 C. The drug-containing layering solution was then sprayed onto the fluidized microcrystalline cellulose particles at a rate of 30 grams/minutes until coated microcrystalline cellulose particles containing approximately 50% by weight of the drug-containing coating were obtained.
Size distribution of drug-lavered particles=
(based on normal distribution model):
Median: 302 microns, Standard deviation: 94 microns Flow analysis demonstrated this material remained free-flowing after 4 days at 40 C / 75% RH. (open dish) . . ~
Examule 5: Tastemasked coated drug-layered particles This example provides a formulation and process for further coating the drug layered particles in example 4 with polymer for tastemasking. In this example, the tastemasking polymer system is a combination of cellulose acetate and Eudragit E-100. Tastemasked coated particles may be prepared by a similar method, using other polymer systems.
A solution was prepared, containing Cellulose Acetate 398-10 and Eudragit E-100 at a level of 12% solids in Acetone (total weight 10.7 kg). The ratio of cellulose acetate to Eudragit E-100 was 95:5.
A portion (3.0 kg) of the drug layered particles produced in example 2 was charged into a Rotor (tangential spray) fluidized bed coating apparatus (Glatt Model GPCG
5/9). The drug-layered particles were then fluidized by a flow of air at an inlet temperature of 36 C. The polymer coating solution was then sprayed onto the fluidized particles at a rate of 35 grams/min. until coated drug particles containing approximately 30% by weight of the polymer coating were obtained.
Size distribution of polymer-coated drug-layered particles (based on normal distribution model):
Median: 309 microns, Standard deviation: 91 microns ~
Ex mple 6 IChewable Tabletsl Tastemasked coated diphenhydramine particles, and tastemasked coated pseudoephedrine hydrochloride particles, prepared in the manner described above, were combined with tastemasked acetaminophen particles (prepared according to methods disclosed in US Patent Number 4,851,226) and the following inactive ingredients to produce chewable tablets, using the process described below:
Material Quantity (mg/
tablet) CA/PVP Coated Acetaminophen (89% potent) 90.91 CA/E100 Coated Pseudoephedrine 21.43 Hydrochloride (35% potent) CA/E100 Coated Diphenhydramine 17.86 Hydrochloride (35% potent) -Mannitol USP (Granular) 284.56 Microcrystalline Cellulose NF 36.0 Aspartame NF 9.6 Flavor 14.6 Color (lakes) 0.24 Magnesium Stearate NF 4.8 Tablet Weight 480 a. All ingredients except magnesium stearate were combined in a PK blender, and blended for 25 minutes. The magnesium stearate was to the blender and blending was continued for an additional 5 minutes.
~
b. Tablets were compressed to the following specifications on a Manesty Betapress using 13/32-inch diameter, round flat-faced beveled edge tooling:
Taraet Weight (mg: average of 10) 480 Thickness (mm: average of 5) 4.8 Hardness (kp: average of 5) 6.0 Friability (% loss: 20 tablets) < 1.0 Resulting tablets had good taste characteristics with minimal bitterness.
Comparative ExamDle 1 Celphere 203 This example provides a formulation and process for layering diphenhydramine onto Celphere 203 (FMC Corp.) a commercially available product marketed as an ideal substrate for drug-layering and particle coating.
A.) An aqueous solution was prepared, containing the following ingredients (total weight 2.68 kg):
Diphenhydramine 56%
Purified Water 44%
Microcrystalline cellulose (Celphere 203, 1.5 kg) was charged into a Rotor (tangential spray) fluidized bed coating apparatus (Glatt Model GPCG 5/9). The Microcrystalline cellulose was then fluidized by a flow of air at an inlet temperature of 34 C. The drug-containing layering solution was then sprayed onto the fluidized Microcrystalline cellulose particles at a rate of 20 grams/min. until coated Microcrystalline cellulose particles containing approximately 50% by weight of the drug-containing coating were obtained.
Flow analysis demonstrated this material became sticky and not free-flowing after 4 days at 40 C / 75% Relative Humidity. (open dish) B.) The drug layered particles were further coated with polymer for tastemasking. In this example, the tastemasking polymer system is a combination of cellulose acetate and Eudragit E-100. A solution was prepared, containing Cellulose Acetate 398-10 and Eudragit E-100 at a level of 12% solids in Acetone (total weight 3.3 kg).
The ratio of cellulose acetate to Eudragit E-100 was 70:30.
A portion (1.0 kg) of the drug layered particles produced in part A was charged into a Rotor (tangential spray) fluidized bed coating apparatus (Glatt Model GPCG
5/9). The drug-layered particles were then fluidized by a flow of air at an inlet temperature of 32 C. The polymer coating solution was then sprayed onto the fluidized particles at a rate of 20 grams/min. until coated drug particles containing approximately 30% by weight of the polymer coating were obtained.
Size distribution of drug-layered particles:
(based on normal distribution model):
Median: 373 microns, Standard deviation: 84 microns Size distribution of polymer-coated, drug-lavered particles (based on normal distribution model):
Median: 399 microns, Standard deviation: 83 microns Comuarative Examole 2 Lactose granules with Methocel E5 (Dow) binder were used as a substrate for layering pseudoephedrine hydrochloride and dextromethorphan hydrobormide, then coating with CA:E100 at a 60 $ level. Resulting tablets were gritty (due to large particle size) and slow to dissolve (due to 60% coating level).
Comparative Example 3 Avicel PH101 (FMC Corp.) was rotor granulated together with pseudoephedrine hydrochloride, dextromethorphan hydrobromide, and chlorpheniramine maleate. Resulting product had median diameter of 51 microns with standard deviation of 270 microns. A high degree of agglomeration and a high degree of fine particles were observed visually.
Comparative Exam lpe 4 Direct coating of the individual (psedoephedrine and i5 diphenhydramine) active particles was attempted, but not pursued further due to excessive agglomeration and poor tastemasking.
Comparative Example 5 Granulating amines (pseudoephedrine and diphenhydramine) together with powdered acetaminophen using water or hydroxypropyl methyl cellulose binder solution was attempted, but not pursued due to a eutectic mixture formation between diphenhydramine and the other ingredients. Moisture adsorption studies suggested that pseudoephedrine and diphenhydramine undergo a solid state interaction at relative humidities > 75% resulting in formation of a deliquescent material.
Claims (11)
1. A pharmaceutical composition comprising particles wherein each of the particles comprises: a center core of greater than 90 weight percent of microcrystalline cellulose having an average core size of 160 to 220 µm with a core size standard deviation of from 75 to 200 µm and having an irregular surface morphology and a non-spherical shape; and a pharmaceutically active material coating the center core of each particle;
wherein each of the coated particles is from 40 to 75 weight percent microcrystalline cellulose;
the pharmaceutically active material is from about 25 to 60 weight percent; and each coated particle has a particle size of from 200 to 325 µm and a particle size standard deviation of from 30 to 175 µm.
wherein each of the coated particles is from 40 to 75 weight percent microcrystalline cellulose;
the pharmaceutically active material is from about 25 to 60 weight percent; and each coated particle has a particle size of from 200 to 325 µm and a particle size standard deviation of from 30 to 175 µm.
2. The pharmaceutical composition of claim 1, wherein the center core is greater than 95 weight percent microcrystalline cellulose.
3. The pharmaceutical composition of claim 1 or 2, wherein the pharmaceutically active material comprises pseudoephedrine and diphenhydramine.
4. The pharmaceutical composition of any one of claims 1 to 3, further comprising a polymer coating over the pharmaceutically active material.
5. The pharmaceutical composition of claim 4, wherein the polymer coating is selected from the group consisting of methylaminoethyl-methacrylate, methacrylic acid esters, cellulose acetate and polyvinylpyrrolidone.
6. A method for making a pharmaceutical composition comprising pharmaceutically active particles as defined in claim 1, wherein the coating of the microcrystalline cellulose is performed in the absence of a granulation step.
7. The method of claim 6, wherein the pharmaceutically active material comprises pseudoephedrine and diphenhydramine.
8. The method of claim 6 or 7, wherein the pharmaceutically active material is deposited on the core via a solution layering process.
9. The method of any one of claims 6 to 8, wherein a polymeric coating is applied over the pharmaceutically active material.
10. The method of claim 9, wherein the polymeric coating is selected from the group consisting of methylaminoethyl-methacrylate, methacrylic acid esters and or cellulose acetate and polyvinylpyrrolidone.
11. The method of claim 10, wherein the coated particles are mixed with an excipient and are compresed to form tablets.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/148,251 US5997905A (en) | 1998-09-04 | 1998-09-04 | Preparation of pharmaceutically active particles |
| US09/148,251 | 1998-09-04 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2281420A1 CA2281420A1 (en) | 2000-03-04 |
| CA2281420C true CA2281420C (en) | 2008-11-18 |
Family
ID=22524956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002281420A Expired - Fee Related CA2281420C (en) | 1998-09-04 | 1999-09-03 | Preparation of pharmaceutically-active granules |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US5997905A (en) |
| EP (1) | EP1000615B1 (en) |
| JP (1) | JP2000109426A (en) |
| CN (1) | CN1151844C (en) |
| AU (1) | AU773833B2 (en) |
| BR (1) | BR9904039A (en) |
| CA (1) | CA2281420C (en) |
| DE (1) | DE69921941T2 (en) |
| ES (1) | ES2233003T3 (en) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW522014B (en) * | 1997-02-07 | 2003-03-01 | Sepracor Inc | Lactose-free, non-hygroscopic and anhydrous pharmaceutical unit dosage form containing descarboethoxyloratadine |
| US5997905A (en) * | 1998-09-04 | 1999-12-07 | Mcneil-Ppc | Preparation of pharmaceutically active particles |
| CA2345945A1 (en) | 1998-10-01 | 2000-04-13 | Powderject Research Limited | Spray coated microparticles for use in needleless syringes |
| US20050214227A1 (en) * | 1999-03-08 | 2005-09-29 | Powderject Research Limited | Microparticle formulations for sustained-release of bioactive compounds |
| ES2162746B1 (en) * | 1999-10-21 | 2003-02-16 | Lipotec Sa | MICROCAPSULES FOR THE STABILIZATION OF COSMETIC, PHARMACEUTICAL OR FOOD PRODUCTS. |
| CA2391243A1 (en) * | 1999-11-12 | 2001-05-17 | R.P. Scherer Technologies, Inc. | Microcrystalline cellulose cushioning granules |
| RS51561B (en) | 2000-02-29 | 2011-08-31 | Bristol-Myers Squibb Co. | Low dose entecavir formulation and use |
| US6392034B1 (en) | 2000-05-17 | 2002-05-21 | Jh Biotech, Inc. | Microcrystalline cellulose |
| US20020051821A1 (en) * | 2000-09-08 | 2002-05-02 | Sung-Yun Kwon | Aliginate particle formulation |
| US6692771B2 (en) | 2001-02-23 | 2004-02-17 | Cima Labs Inc. | Emulsions as solid dosage forms for oral administration |
| AU2001241730B2 (en) * | 2001-02-23 | 2007-03-15 | Cima Labs Inc. | Emulsions as solid dosage forms for oral administration |
| US20030096791A1 (en) * | 2001-05-31 | 2003-05-22 | Cima Labs Inc. | Taste masking of highly water-soluble drugs |
| JP2005506323A (en) * | 2001-09-05 | 2005-03-03 | ベクトゥラ・リミテッド | Functional powder for oral delivery |
| US6767200B2 (en) | 2001-09-28 | 2004-07-27 | Mcneil-Ppc, Inc. | Systems, methods and apparatuses for manufacturing dosage forms |
| US6982094B2 (en) | 2001-09-28 | 2006-01-03 | Mcneil-Ppc, Inc. | Systems, methods and apparatuses for manufacturing dosage forms |
| US7122143B2 (en) | 2001-09-28 | 2006-10-17 | Mcneil-Ppc, Inc. | Methods for manufacturing dosage forms |
| EP1429737A1 (en) | 2001-09-28 | 2004-06-23 | McNEIL-PPC, INC. | Modified release dosage forms |
| US7217381B2 (en) | 2001-09-28 | 2007-05-15 | Mcneil-Ppc, Inc. | Systems, methods and apparatuses for manufacturing dosage forms |
| US6742646B2 (en) * | 2001-09-28 | 2004-06-01 | Mcneil-Ppc, Inc. | Systems, methods and apparatuses for manufacturing dosage forms |
| US6837696B2 (en) * | 2001-09-28 | 2005-01-04 | Mcneil-Ppc, Inc. | Apparatus for manufacturing dosage forms |
| US7838026B2 (en) | 2001-09-28 | 2010-11-23 | Mcneil-Ppc, Inc. | Burst-release polymer composition and dosage forms comprising the same |
| US7323192B2 (en) | 2001-09-28 | 2008-01-29 | Mcneil-Ppc, Inc. | Immediate release tablet |
| IL146462A (en) * | 2001-11-13 | 2015-02-26 | Lycored Bio Ltd | Extended release compositions comprising as active compound venlafaxine hydrochloride |
| UA76810C2 (en) | 2001-12-10 | 2006-09-15 | Мерк Енд Ко., Інк. | Pharmaceutical compositions of tachikinine receptor antagonist in form of nanoparticles |
| CO5400144A1 (en) * | 2002-03-11 | 2004-05-31 | Novartis Ag | ORGANIC COMPOUNDS |
| TWI275392B (en) * | 2002-04-08 | 2007-03-11 | Bristol Myers Squibb Co | Low dose liquid entecavir formulations and use |
| US20040033257A1 (en) * | 2002-05-30 | 2004-02-19 | Strides Inc. | Pharmaceutical formulation in a drug delivery system and process for preparing the same |
| US7807197B2 (en) | 2002-09-28 | 2010-10-05 | Mcneil-Ppc, Inc. | Composite dosage forms having an inlaid portion |
| ATE359075T1 (en) * | 2002-12-20 | 2007-05-15 | Niconovum Ab | CHEMICALLY AND PHYSICALLY STABLE PARTICLE MATERIAL CONTAINING NICOTINE AND MICROCRYSTALLINE CELLULOSE |
| EA010905B1 (en) * | 2003-09-17 | 2008-12-30 | Янссен Фармацевтика Н.В. | Fused heterocyclic compounds |
| US20050074514A1 (en) * | 2003-10-02 | 2005-04-07 | Anderson Oliver B. | Zero cycle molding systems, methods and apparatuses for manufacturing dosage forms |
| US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
| FR2864962B1 (en) * | 2004-01-08 | 2007-09-14 | Seppic Sa | NOVEL POROUS FILMOGENOUS GRANULES, PROCESS FOR THEIR PREPARATION AND APPLICATION IN THE PACKING OF TABLETS AND CONFECTIONERY |
| JP2005306778A (en) * | 2004-04-21 | 2005-11-04 | Basf Ag | Sustained-release formulation and method for producing the same |
| US20060019933A1 (en) * | 2004-07-22 | 2006-01-26 | David Boardman | Process for preparing stabilized vitamin D |
| DE102004035938A1 (en) * | 2004-07-23 | 2006-02-16 | Röhm GmbH & Co. KG | Process for the preparation of coated drug forms with stable drug release profile |
| US20070077297A1 (en) * | 2004-09-30 | 2007-04-05 | Scolr Pharma, Inc. | Modified release ibuprofen dosage form |
| US20060068009A1 (en) * | 2004-09-30 | 2006-03-30 | Scolr Pharma, Inc. | Modified release ibuprofen dosage form |
| US20060127479A1 (en) * | 2004-10-08 | 2006-06-15 | Natrajan Kumaraperumal | Solvent free taste masked pharmaceutical compositions |
| ES2231043B2 (en) * | 2004-10-29 | 2005-10-01 | Laboratorios Cinfa, S.A. | PHARMACEUTICAL COMPOSITION OF EBASTINE FOR IMMEDIATE RELEASE AND ITS MANUFACTURING PROCESS. |
| WO2006055742A1 (en) * | 2004-11-18 | 2006-05-26 | Bristol-Myers Squibb Company | Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof |
| ATE397442T1 (en) * | 2004-11-18 | 2008-06-15 | Bristol Myers Squibb Co | ENTERIC JUICE RESISTANT COATED PELLET WITH IXABEPILONE |
| US8673352B2 (en) | 2005-04-15 | 2014-03-18 | Mcneil-Ppc, Inc. | Modified release dosage form |
| US20080020040A1 (en) * | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Unit dose form for administration of ibuprofen |
| US8067451B2 (en) * | 2006-07-18 | 2011-11-29 | Horizon Pharma Usa, Inc. | Methods and medicaments for administration of ibuprofen |
| US20080021078A1 (en) * | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Methods and medicaments for administration of ibuprofen |
| US20070043097A1 (en) * | 2005-07-18 | 2007-02-22 | Horizon Therapeutics, Inc. | Medicaments containing famotidine and ibuprofen and administration of same |
| US7598255B2 (en) | 2005-08-04 | 2009-10-06 | Janssen Pharmaceutica Nv | Pyrimidine compounds as serotonin receptor modulators |
| US8815285B2 (en) * | 2006-03-28 | 2014-08-26 | Wockhardt Ltd. | Extended release dosage forms of metoprolol |
| US20090069343A1 (en) * | 2006-04-10 | 2009-03-12 | Dunford Paul J | Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus |
| US8067033B2 (en) * | 2007-11-30 | 2011-11-29 | Horizon Pharma Usa, Inc. | Stable compositions of famotidine and ibuprofen |
| CN101489536B (en) * | 2006-07-19 | 2011-11-16 | 旭化成化学株式会社 | Process for producing spherical elementary granule containing readily water-soluble drug |
| US20090196934A1 (en) * | 2006-07-26 | 2009-08-06 | Asahi Kasei Chemicals Corporation | Spherical elementary granule and method for production thereof |
| US20100297224A1 (en) * | 2006-08-31 | 2010-11-25 | Horizon Therapeutics, Inc. | NSAID Dose Unit Formulations with H2-Receptor Antagonists and Methods of Use |
| EP2091515B1 (en) | 2006-11-21 | 2014-06-04 | McNeil-PPC, Inc. | Modified release analgesic suspensions |
| US8298585B2 (en) * | 2007-06-06 | 2012-10-30 | Asahi Kasei Chemicals Corporation | Cellulose-based fine core particle and process for producing the same |
| US9833510B2 (en) * | 2007-06-12 | 2017-12-05 | Johnson & Johnson Consumer Inc. | Modified release solid or semi-solid dosage forms |
| CN101842085B (en) | 2007-10-31 | 2013-01-30 | 麦克内尔-Ppc股份有限公司 | Orally disintegrated dosage form |
| WO2010057870A1 (en) | 2008-11-18 | 2010-05-27 | Ucb Pharma, S.A. | Prolonged release formulations comprising an 2 -oxo- 1 -pyrrolidine derivative |
| US9610224B2 (en) | 2009-09-24 | 2017-04-04 | Johnson & Johnson Consumer Inc. | Manufacture of tablet in a die utilizing powder blend containing water-containing material |
| US8858210B2 (en) | 2009-09-24 | 2014-10-14 | Mcneil-Ppc, Inc. | Manufacture of variable density dosage forms utilizing radiofrequency energy |
| US8313768B2 (en) | 2009-09-24 | 2012-11-20 | Mcneil-Ppc, Inc. | Manufacture of tablet having immediate release region and sustained release region |
| EP2488029B1 (en) * | 2009-09-30 | 2016-03-23 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse |
| GB2479213B (en) * | 2010-04-01 | 2013-07-10 | Theravida Inc | Pharmaceutical formulations for the treatment of overactive bladder |
| CN102641496A (en) | 2011-02-16 | 2012-08-22 | 辛绍祺 | New application and composition of high-molecular polymer |
| US8940763B2 (en) | 2011-05-10 | 2015-01-27 | Theravida, Inc. | Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder |
| CN102579367B (en) * | 2012-03-23 | 2014-03-12 | 中国人民解放军军事医学科学院毒物药物研究所 | Topiramate sustained-release drug composition, method for preparing same and application of Topiramate sustained-release drug composition |
| US9233491B2 (en) | 2012-05-01 | 2016-01-12 | Johnson & Johnson Consumer Inc. | Machine for production of solid dosage forms |
| US9445971B2 (en) | 2012-05-01 | 2016-09-20 | Johnson & Johnson Consumer Inc. | Method of manufacturing solid dosage form |
| US9511028B2 (en) | 2012-05-01 | 2016-12-06 | Johnson & Johnson Consumer Inc. | Orally disintegrating tablet |
| US9101636B2 (en) | 2012-11-30 | 2015-08-11 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
| CA2936216C (en) | 2014-01-10 | 2021-10-26 | Johnson & Johnson Consumer Inc. | Process for making tablet using radiofrequency and lossy coated particles |
| EP3122336A4 (en) | 2014-03-26 | 2017-10-25 | Sun Pharma Advanced Research Company Ltd | Abuse deterrent immediate release biphasic matrix solid dosage form |
| EP3157516A4 (en) | 2014-06-22 | 2017-12-13 | Dexcel Pharma Technologies Ltd. | Pharmaceutical compositions comprising ferric citrate and methods for the production thereof |
| US10114116B2 (en) | 2014-08-19 | 2018-10-30 | Navico Holding As | Common burst for pulse compression radar |
| WO2017040607A1 (en) | 2015-08-31 | 2017-03-09 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
| CN108697688A (en) | 2016-01-20 | 2018-10-23 | 塞拉维达公司 | Method and composition for treating ephidrosis |
| US10493026B2 (en) | 2017-03-20 | 2019-12-03 | Johnson & Johnson Consumer Inc. | Process for making tablet using radiofrequency and lossy coated particles |
| WO2018200857A1 (en) * | 2017-04-26 | 2018-11-01 | Cornell University | Grafted porous cyclodextrin polymeric material and methods of making and using same |
| DE102019200135A1 (en) | 2019-01-08 | 2020-07-09 | Beiersdorf Ag | Preparation with silica particles coated with vinylamine / N-vinylformamide copolymer |
| DE102019200138A1 (en) | 2019-01-08 | 2020-07-09 | Beiersdorf Ag | Preparation with cellulose particles coated with vinylamine / N-vinylformamide copolymer |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4851226A (en) * | 1987-11-16 | 1989-07-25 | Mcneil Consumer Products Company | Chewable medicament tablet containing means for taste masking |
| FR2624732B1 (en) * | 1987-12-21 | 1991-02-15 | Synthelabo | SUSTAINED RELEASE PHARMACEUTICAL FORMULATION |
| US5077051A (en) * | 1990-04-10 | 1991-12-31 | Warner-Lambert Company | Sustained release of active agents from bioadhesive microcapsules |
| DE69111287T2 (en) * | 1990-04-18 | 1995-12-21 | Asahi Chemical Ind | Spherical nuclei, spherical granules and processes for their production. |
| JP2542122B2 (en) * | 1990-04-18 | 1996-10-09 | 旭化成工業株式会社 | Spherical nucleus, spherical granule and method for producing the same |
| JPH10182438A (en) * | 1991-03-07 | 1998-07-07 | Takeda Chem Ind Ltd | Powdery preparation having nucleus |
| CA2062697C (en) * | 1991-03-22 | 1997-04-22 | Charles W. Connors, Jr. | Method and apparatus for manufacturing and repairing molten metal containment vessels |
| JP2892858B2 (en) * | 1991-05-15 | 1999-05-17 | 田辺製薬株式会社 | Controlled release formulation and method for producing the same |
| CA2068402C (en) * | 1991-06-14 | 1998-09-22 | Michael R. Hoy | Taste mask coatings for preparation of chewable pharmaceutical tablets |
| GB9114374D0 (en) * | 1991-07-03 | 1991-08-21 | Smithkline Beecham Plc | Novel process |
| FR2682874B1 (en) * | 1991-10-24 | 1993-12-10 | Rinrone Ets | PROCESS FOR THE PREPARATION OF AN EXTRACT OF ACTIVE PRINCIPLES IN THE DRY ADSORBABLE FORM AND ADSORBABLE MICROGRANULES THUS OBTAINED. |
| HU217629B (en) * | 1991-12-12 | 2000-03-28 | Novartis Ag. | Process for producing stabilized pharmaceutical compositions comprising fluvastatin |
| JPH05213740A (en) * | 1992-02-04 | 1993-08-24 | Dainippon Pharmaceut Co Ltd | Granular pharmaceutical preparation |
| US5429825A (en) * | 1992-06-26 | 1995-07-04 | Mcneil-Ppc, Inc. | Rotomelt granulation |
| AU5592694A (en) * | 1992-11-05 | 1994-05-24 | Merck & Co., Inc. | Drug delivery device |
| DE69524527D1 (en) * | 1994-10-14 | 2002-01-24 | Japan Energy Corp | AIDS-inhibiting drug preparation and method |
| US5529783A (en) * | 1994-12-19 | 1996-06-25 | Mcneil-Ppc, Inc. | Rotor granulation and coating of acetaminophen, pseudoephedrine, chlorpheniramine, and, optionally dextromethorphan |
| US5547948A (en) * | 1995-01-17 | 1996-08-20 | American Home Products Corporation | Controlled release of steroids from sugar coatings |
| US5573783A (en) * | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
| TW289733B (en) * | 1995-05-05 | 1996-11-01 | Hua Shin Chemical Pharmaceutical Works Co Ltd | Process for preparing round pellets of Omeprazole for oral administration |
| JP3833314B2 (en) * | 1995-09-08 | 2006-10-11 | 武田薬品工業株式会社 | Foamable composition and method for producing the same |
| US5780055A (en) * | 1996-09-06 | 1998-07-14 | University Of Maryland, Baltimore | Cushioning beads and tablet comprising the same capable of forming a suspension |
| US5997905A (en) * | 1998-09-04 | 1999-12-07 | Mcneil-Ppc | Preparation of pharmaceutically active particles |
-
1998
- 1998-09-04 US US09/148,251 patent/US5997905A/en not_active Expired - Lifetime
-
1999
- 1999-09-02 BR BR9904039-5A patent/BR9904039A/en not_active Application Discontinuation
- 1999-09-02 AU AU47350/99A patent/AU773833B2/en not_active Ceased
- 1999-09-03 JP JP11250489A patent/JP2000109426A/en active Pending
- 1999-09-03 ES ES99307051T patent/ES2233003T3/en not_active Expired - Lifetime
- 1999-09-03 CA CA002281420A patent/CA2281420C/en not_active Expired - Fee Related
- 1999-09-03 EP EP99307051A patent/EP1000615B1/en not_active Expired - Lifetime
- 1999-09-03 DE DE69921941T patent/DE69921941T2/en not_active Expired - Lifetime
- 1999-09-03 CN CNB991186117A patent/CN1151844C/en not_active Expired - Fee Related
- 1999-11-02 US US09/431,899 patent/US6149943A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1000615A3 (en) | 2000-05-31 |
| ES2233003T3 (en) | 2005-06-01 |
| DE69921941D1 (en) | 2004-12-23 |
| EP1000615B1 (en) | 2004-11-17 |
| DE69921941T2 (en) | 2005-12-01 |
| CN1151844C (en) | 2004-06-02 |
| BR9904039A (en) | 2001-01-16 |
| AU773833B2 (en) | 2004-06-10 |
| US5997905A (en) | 1999-12-07 |
| CN1249950A (en) | 2000-04-12 |
| CA2281420A1 (en) | 2000-03-04 |
| AU4735099A (en) | 2000-03-16 |
| US6149943A (en) | 2000-11-21 |
| JP2000109426A (en) | 2000-04-18 |
| EP1000615A2 (en) | 2000-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2281420C (en) | Preparation of pharmaceutically-active granules | |
| EP1094788B1 (en) | Croscarmellose taste masking | |
| KR100316206B1 (en) | Controlled Release Formulations Containing Salts of Morphine | |
| EP0717986B1 (en) | Rotor granulation and coating of acetaminophen, pseudoephedrine, chlorpheniramine, and, optionally, dextromethorphan | |
| JP3157190B2 (en) | Taste masking and long acting coatings for drugs | |
| US5411745A (en) | Powder-layered morphine sulfate formulations | |
| US6077533A (en) | Powder-layered oral dosage forms | |
| KR950005864B1 (en) | Sustained-release formulation | |
| AU760006B2 (en) | Method for making granules with masked taste and instant release of the active particle | |
| CA2211284C (en) | Multiple unit sustained release dosage form | |
| US8557282B2 (en) | Extended release compositions comprising as active compound venlafaxine hydrochloride | |
| US4780318A (en) | Oral pharmaceutical composition | |
| CA2038245C (en) | Pharmaceutically useful micropellets | |
| EP1748764B1 (en) | An amine drug-containing slow-release granule preparation based on particles with a coating layer and the corresponding method of production | |
| CA2606813A1 (en) | Timed, pulsatile release systems | |
| HRP20010198A2 (en) | Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same | |
| HU193359B (en) | Process for preparing a delayed theophylline composition | |
| WO2004087111A1 (en) | Oral taste masked pharmaceutical compositions | |
| US7060293B1 (en) | Powder-layered oral dosage forms | |
| CA1336326C (en) | Microbeads of diltiazem, a process for their manufacture and a sustained-release pharmaceutical composition containing them | |
| AU6224699A (en) | Taste masking coating compositions | |
| JP3343144B2 (en) | Micro capsule | |
| JPH08175977A (en) | Release control type pharmaceutical preparation coated with aqueous dispersion of acrylic polymer and its preparation | |
| WO2005016317A1 (en) | Process for manufacture of extended release pellets containing diltiazem hci |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20160906 |